A comprehensive view of new dosage/format. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

ViiV Healthcare, Janssen Pharmaceutical receive FDA approval for label update for Cabenuva cabotegravir, non-nucleoside reverse transcriptase inhibitor rilpivirine injectable to treat HIV-1; approved dose is once-monthly or once every two months
Published: March 30, 2022 by Fitch Solutions Sector Intelligence
CanSinoBIO's Convidecia approved in Malaysia as a heterologous booster for individuals aged 18 and older who have received two doses of inactivated COVID-19 vaccine
Published: March 22, 2022 by Canada Newswire
FDA revises emergency use authorization for AstraZeneca's Evusheld prophylaxis treatment for COVID-19; revised regimen offers a higher dose due to evidence suggesting lower effectiveness against Omicron subvariants
Published: February 25, 2022 by U.S. Food and Drug Administration (FDA)
Pfizer to postpone application to the FDA for its coronavirus vaccine in children aged six months to four years; company will await data from ongoing clinical study evaluating a third dose
Published: February 16, 2022 by Gov Japan Live
Takeda announces FDA approval of the TAKHZYRO injection single-dose prefilled syringe for treatment of hereditary angioedema; approval offers new option in addition to vial injection
Published: February 09, 2022 by Takeda Pharmaceutical Co. Ltd.

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count